Lawrence Kushi to Aromatase Inhibitors
This is a "connection" page, showing publications Lawrence Kushi has written about Aromatase Inhibitors.
Connection Strength
0.718
-
Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy. Breast Cancer Res Treat. 2018 Apr; 168(2):523-530.
Score: 0.149
-
Patterns and reasons for switching classes of hormonal therapy among women with early-stage breast cancer. Cancer Causes Control. 2017 Jun; 28(6):557-562.
Score: 0.141
-
Bone health history in breast cancer patients on aromatase inhibitors. PLoS One. 2014; 9(10):e111477.
Score: 0.120
-
Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011 Apr; 126(2):529-37.
Score: 0.090
-
Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010 Sep 20; 28(27):4120-8.
Score: 0.089
-
Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer. Breast Cancer Res Treat. 2023 Aug; 201(1):117-126.
Score: 0.054
-
Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study. Breast Cancer Res Treat. 2020 Feb; 180(1):187-195.
Score: 0.043
-
Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL). Breast Cancer Res Treat. 2016 05; 157(1):133-43.
Score: 0.033